| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;111:871-878.)
© 2005 American Heart Association, Inc.
Heart Failure |
From the Divisions of Cardiovascular Diseases (V.S.C., Y.S., K.T.W.) and Endocrinology (I.C.G.), Department of Medicine, and Departments of Surgery (S.K.B.), Obstetrics and Gynecology (R.A.A.), Pediatrics (L.K.M.), and Orthopaedic Surgery (Z.X., R.A.S.), University of Tennessee Health Science Center, Memphis.
Correspondence to Karl T. Weber, MD, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, 920 Madison Ave, Ste 300, Memphis, TN 38163. E-mail KTWeber{at}utmem.edu
Received October 6, 2004; revision received November 5, 2004; accepted November 10, 2004.
Background Aldosteronism may account for oxi/nitrosative stress, a proinflammatory phenotype, and wasting in congestive heart failure. We hypothesized that aldosterone/1% NaCl treatment (ALDOST) in rats enhances Ca2+ and Mg2+ excretion and leads to systemic effects, including bone loss.
Methods and Results At 1, 2, 4, and 6 weeks of ALDOST, we monitored Ca2+ and Mg2+ excretion, ionized [Ca2+]o and [Mg2+]o, parathyroid hormone and
1-antiproteinase activity in plasma, bone mineral density, bone strength, Ca2+ and Mg2+ content in peripheral blood mononuclear cells (PBMCs) and ventricular tissue, and lymphocyte H2O2 production. A separate group received spironolactone (Spiro), an aldosterone receptor antagonist. Age- and gender-matched unoperated and untreated rats served as controls. ALDOST induced a marked (P<0.05) and persistent rise in urinary and fecal Ca2+ and Mg2+ excretion, a progressive reduction (P<0.05) in [Ca2+]o and [Mg2+]o, and an elevation in parathyroid hormone (P<0.05) with a fall (P<0.05) in bone mineral density and strength. An early, sustained increase (P<0.05) in PBMC Ca2+ and Mg2+ was found, together with an increase (P<0.05) in tissue Ca2+. Plasma
1-antiproteinase activity was reduced (P<0.05), whereas lymphocyte H2O2 production was increased (P<0.05) at all time points. Spiro cotreatment attenuated (P<0.05) urinary and fecal Ca2+ and Mg2+ excretion, prevented the fall in [Ca2+]o and [Mg2+]o, rescued bone mineral density and strength, and prevented Ca2+ overloading of PBMCs and cardiomyocytes.
Conclusions In aldosteronism, Ca2+ and Mg2+ losses lead to a fall in [Ca2+]o and [Mg2+]o with secondary hyperparathyroidism and bone resorption. Ca2+ overloading of PBMCs and cardiac tissue leads to oxi/nitrosative stress and a proinflammatory phenotype.
Key Words: aldosterone calcium magnesium osteoporosis parathyroid hormone
Related Article:
Circulation 2005 111: 830-831.
This article has been cited by other articles:
![]() |
L. D. Carbone, J. D. Cross, S. H. Raza, A. J. Bush, R. J. Sepanski, S. Dhawan, B. Q. Khan, M. Gupta, K. Ahmad, R. N. Khouzam, et al. Fracture Risk in Men With Congestive Heart Failure Risk Reduction With Spironolactone. J. Am. Coll. Cardiol., July 8, 2008; 52(2): 135 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T Weber, R. U Simpson, and L. D Carbone Vitamin D and calcium dyshomoeostasis-associated heart failure Heart, May 1, 2008; 94(5): 540 - 541. [Full Text] [PDF] |
||||
![]() |
B. Sontia, A. C.I. Montezano, T. Paravicini, F. Tabet, and R. M. Touyz Downregulation of Renal TRPM7 and Increased Inflammation and Fibrosis in Aldosterone-Infused Mice: Effects of Magnesium Hypertension, April 1, 2008; 51(4): 915 - 921. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Varagic, E. D. Frohlich, D. Susic, J. Ahn, L. Matavelli, B. Lopez, and J. Diez AT1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H853 - H858. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Alsafwah, S. P. LaGuardia, M. Arroyo, B. K. Dockery, S. K. Bhattacharya, R. A. Ahokas, and K. P. Newman Congestive Heart Failure is a Systemic Illness: A Role for Minerals and Micronutrients Clin. Med. Res., December 1, 2007; 5(4): 238 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Thomas, A. Vidal, S. K. Bhattacharya, R. A. Ahokas, Y. Sun, I. C. Gerling, and K. T. Weber Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2361 - H2366. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sun, R. A. Ahokas, S. K. Bhattacharya, I. C. Gerling, L. D. Carbone, and K. T. Weber Oxidative stress in aldosteronism Cardiovasc Res, July 15, 2006; 71(2): 300 - 309. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vidal, Y. Sun, S. K. Bhattacharya, R. A. Ahokas, I. C. Gerling, and K. T. Weber Calcium paradox of aldosteronism and the role of the parathyroid glands Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H286 - H294. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Stowasser, J. Sharman, R. Leano, R. D. Gordon, G. Ward, D. Cowley, and T. H. Marwick Evidence for Abnormal Left Ventricular Structure and Function in Normotensive Individuals with Familial Hyperaldosteronism Type I J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5070 - 5076. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. Law, Y. Sun, S. K. Bhattacharya, V. S. Chhokar, and K. T. Weber Diuretics and Bone Loss in Rats With Aldosteronism J. Am. Coll. Cardiol., July 5, 2005; 46(1): 142 - 146. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Schiffrin and R. M. Touyz Calcium, Magnesium, and Oxidative Stress in Hyperaldosteronism Circulation, February 22, 2005; 111(7): 830 - 831. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |